1. Home
  2. ADI vs NVO Comparison

ADI vs NVO Comparison

Compare ADI & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Analog Devices Inc.

ADI

Analog Devices Inc.

HOLD

Current Price

$384.64

Market Cap

179.0B

Sector

Technology

ML Signal

HOLD

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

HOLD

Current Price

$46.00

Market Cap

208.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADI
NVO
Founded
1965
1923
Country
United States
Denmark
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
179.0B
208.2B
IPO Year
1994
2001

Fundamental Metrics

Financial Performance
Metric
ADI
NVO
Price
$384.64
$46.00
Analyst Decision
Buy
Hold
Analyst Count
22
11
Target Price
$385.45
$51.00
AVG Volume (30 Days)
3.7M
11.3M
Earning Date
05-20-2026
05-06-2026
Dividend Yield
1.13%
3.19%
EPS Growth
39.02
N/A
EPS
4.09
N/A
Revenue
$6,200,942,000.00
N/A
Revenue This Year
$28.41
N/A
Revenue Next Year
$10.25
$3.70
P/E Ratio
$93.21
$13.60
Revenue Growth
21.41
N/A
52 Week Low
$223.47
$35.12
52 Week High
$449.52
$64.16

Technical Indicators

Market Signals
Indicator
ADI
NVO
Relative Strength Index (RSI) 51.13 43.25
Support Level $375.59 $45.62
Resistance Level $404.53 $46.92
Average True Range (ATR) 10.83 1.37
MACD 2.32 -0.27
Stochastic Oscillator 71.19 26.79

Price Performance

Historical Comparison
ADI
NVO

About ADI Analog Devices Inc.

Analog Devices is a leading analog, mixed-signal, and digital-signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers; more than half of its chip sales are to industrial and automotive end markets. ADI's chips are also incorporated into wireless infrastructure equipment.

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: